ZGEN "I assume the main reason for wanting to replace interferon therapy with a strictly oral small-molecule regimen is due to the side effects of interferon. Again, this may not be as much of an issue with IFN-Lambda given its potential for much improved tolerability compared to current interferon treatment."
it is conceivable that IN lambda will have a more favorable tolerability profile than some of the direct acting antivirals even factoring in the fact it is a weekly injection
re inform-1 - there will be data on early viral kinetics and tolerability, but there will be no readout on the bigger hurdle of viral breakthrough on longer treatment duration and most importantly relapse since every arm gets SOC after the initial protease/polymerase combo
lastly, even if/when all oral cocktails become standard, unless you think cure rates approach 100%, there is bound to be a role for interferon in refractory settings
Market Data 
Markets 
AI
